Zevra Therapeutics (ZVRA) Profit After Tax (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Profit After Tax of $37.9 million for Q1 2026, up 211.47% on a QoQ basis from $12.2 million in Q4 2025, and up 1322.65% year-over-year from $2.7 million in Q1 2025.
Zevra Therapeutics (ZVRA) Profit After Tax (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Profit After Tax history runs 13 years deep, the most recent figure standing at $37.9 million for Q1 2026.
- Quarterly Profit After Tax rose 1322.65% year-over-year to $37.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.2 million (up 235.04% YoY) and the FY2025 annual result came in at $83.2 million, up 178.88% from the prior year.
- Profit After Tax was $37.9 million for Q1 2026 at Zevra Therapeutics, up from $12.2 million in the prior quarter.
- Across five years, Profit After Tax topped out at $74.7 million in Q2 2025 and bottomed at -$35.7 million in Q4 2024.
- A 5-year average of -$1.9 million and a median of -$4.9 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2024 — Profit After Tax sank 674.39% — and 2026, when it jumped 1322.65%.
- Zevra Therapeutics' Profit After Tax stood at $5.8 million in 2022, then plunged by 218.26% to -$6.8 million in 2023, then slumped by 425.57% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025, then soared by 211.47% to $37.9 million in 2026.
- Business Quant data shows ZVRA's Profit After Tax at $37.9 million in Q1 2026, $12.2 million in Q4 2025, and -$544000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | -453.82 Mn |
| 10 | Zevra Therapeutics | 574.72 Mn | 374.10 Mn | 34.32 Mn | 37.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.89 Mn |
| Dec 31, 2025 | 12.17 Mn |
| Sep 30, 2025 | -544,000.00 |
| Jun 30, 2025 | 74.71 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -35.74 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.93 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -6.80 Mn |
| Sep 30, 2023 | -25.90 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -13.22 Mn |
| Dec 31, 2022 | 5.75 Mn |
| Dec 31, 2021 | -2.70 Mn |
| Sep 30, 2021 | -1.76 Mn |
| Jun 30, 2021 | 6.20 Mn |
| Mar 31, 2021 | -10.30 Mn |
| Dec 31, 2020 | -4.86 Mn |
| Sep 30, 2020 | -3.01 Mn |